{
    "clinical_study": {
        "@rank": "100958", 
        "arm_group": {
            "arm_group_label": "F8IL10 + methotrexate", 
            "arm_group_type": "Experimental", 
            "description": "F8IL10 in combination with methotrexate. This study foresees one arm of treatment with several coohorts aimed to increase the dosage of F8IL10.\nIn the study cohorts a fixed dose of MTX (10-15 mg) and  increasing doses of F8IL10 (starting from 6 \u03bcg/kg cohort 1) will be administered. Both drugs will be administered on day 1.\nIn all coohorts a stable dose of folic acid (5 mg) will be administered on day 2"
        }, 
        "brief_summary": {
            "textblock": "Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of\n      F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients."
        }, 
        "brief_title": "Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of\n      F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.\n      Interleukin-10 (IL10) is a cytokine naturally produced by activated monocytes and T-cells.\n      It is deeply involved in the regulation of inflammatory responses and immune reactions.\n      Therefore, IL10 has been considered an attractive candidate for therapeutic use based on its\n      potent in vitro immunomodulating activities and proven effects in animal models of acute and\n      chronic inflammation, autoimmunitiy, cancer and infectious disease.\n\n      In the F8IL10 molecule, IL10 is coupled to the antibody fragment F8 which binds to the\n      extra-domain A of fibronectin, which is selectively expressed at newly formed blood vessels\n      within inflammatory tissues.Upon injection into a patient F8IL10 is supposed to accumulate\n      at the site of arthritis where it exerts its biological activity.\n\n      Antibody-mediated targeted delivery of cytokines to sites of disease is a novel therapeutic\n      concept which is largely unexplored for the treatment of chronic inflammatory conditions,\n      but has been investigated successfully in the cancer setting over the last few years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged >/=18 and < 75 years\n\n          2. Diagnosis of RA according to ACR criteria (1987) with a disease duration exceeding 12\n             months\n\n          3. Active RA (DAS28 >/=3.2) for >/=4 months at time of signing informed consent\n\n          4. Receiving treatment on an outpatient basis\n\n          5. Methotrexate at 10-15 mg/w for a period >/=8 weeks prior to treatment\n\n          6. Inadequate clinical response to at least one anti-TNF therapy applied for at least 4\n             months\n\n          7. If patients are receiving an oral corticosteroid, the dose must have been stable for\n             at least 25 out of 28 days prior to study treatment and the dose must be less than 10\n             mg/day (prednisolone equivalent)\n\n          8. All acute toxic effects of any prior therapy must have returned to classification\n             \"mild\". according to RCTC V.2.0\n\n          9. Sufficient hematologic, liver and renal function:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5 x 10^9/L, platelets \u2265 100 x 10^9/L,\n                  hemoglobin (Hb) \u2265 9.5 g/dL\n\n               -  Alkaline phosphatase (AP), alanine aminotransferase (ALT) and or aspartate\n                  aminotransferase (AST) \u2264 3 x upper limit of normal range (ULN), and total\n                  bilirubin \u2264 2.0 mg/dL (34.2 \u00b5mol/L)\n\n               -  Creatinine \u2264 1.5 ULN or 24 h creatinine clearance \u2265 50 mL/min\n\n         10. Documented negative test for human immunodeficiency virus, HBV, and HCV\n\n         11. Male and female patients, who are potentially fertile, must agree to use adequate\n             contraceptive methods at the beginning of the screening visit that must be continued\n             until 3 months following the last treatment with study drug.\n\n         12. Negative serum pregnancy test (for women of child-bearing potential only) at\n             screening\n\n         13. Signed and dated Ethics Committee-approved Informed Consent Form indicating that the\n             patient (or legally acceptable representative) has been informed of all pertinent\n             aspects of the study\n\n         14. Willingness and ability to comply with the scheduled visits, treatment plan,\n             laboratory tests and other study procedures\n\n        Exclusion Criteria:\n\n          1. Presence of active infections (e.g. requiring antibiotic therapy) or other severe\n             concurrent disease, which, in the opinion of the investigator, would place the\n             patient at undue risk or would interfere with the study objectives or conduct.\n\n          2. Pregnancy, lactation or unwillingness to use adequate contraceptive methods.\n\n          3. Active or latent tuberculosis (TB)\n\n          4. Chronic active hepatitis or active autoimmune diseases other than RA\n\n          5. History of currently active primary or secondary immunodeficiency\n\n          6. HIV Infection\n\n          7. Acute or chronic-active infection with HBV or HCV\n\n          8. Evidence of active malignant disease at screening or advanced malignancies diagnosed\n             within the previous 5 years\n\n          9. Any previous treatment with alkylating agents, such as cyclophosphamide or\n             chlorambucil or with total lymphoid irradiation\n\n         10. History within the last year of acute or subacute coronary syndromes including\n             myocardial infarction, unstable or severe stable angina pectoris\n\n         11. Treatment with warfarin or other coumarin derivatives\n\n         12. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)\n\n         13. Irreversible cardiac arrhythmias requiring permanent medication\n\n         14. Clinically significant (to clinical investigator's discretion) abnormalities in\n             baseline MUGA, ECHO or ECG analyses\n\n         15. Uncontrolled hypertension\n\n         16. Ischemic peripheral vascular disease (Grade IIb-IV)\n\n         17. Severe diabetic retinopathy\n\n         18. Major trauma including surgery within 4 weeks of administration of study treatment\n\n         19. Known history of allergy or other intolerance to IL10, methotrexate, folic acid or\n             other drugs based on human proteins/peptides/antibodies\n\n         20. In vivo exposure to monoclonal antibodies for biological therapy (e.g. etanercept,\n             adalimumab and infliximab) 8 weeks prior to administration of study medication\n\n         21. Treatment with any investigational agent within the 6 weeks before study treatment\n\n         22. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline\n\n         23. Growth factors or immunomodulatory agents within 7 days of the administration of\n             study treatment\n\n         24. Neuropathy > Grade 1 or Neuropathies or other painful conditions (not RA-related)\n             that might interfere with pain evaluation\n\n         25. Patients required to be treated with corticosteroids at a dose > 10 mg/day or with\n             immunosuppressant drugs other than MTX on a long-term basis. Limited use of\n             corticosteroids to treat or prevent acute hypersensitivity reactions is not\n             considered an exclusion criterion.\n\n         26. History of alcohol, drug or chemical substance abuse within the 6 months prior to\n             screening\n\n         27. Body weight of >100 kg\n\n         28. Any condition that in the opinion of the investigator could hamper compliance with\n             the study protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076659", 
            "org_study_id": "PH-F8IL10-02/08", 
            "secondary_id": "2008-008729-31"
        }, 
        "intervention": {
            "arm_group_label": "F8IL10 + methotrexate", 
            "description": "Weekly administration of F8IL10 (from 6 to 210 \u03bcg/kg) + MTX (10-15 mg, fixed dose) on Day 1 and Folic acid (5 mg, fixed dose) on Day 2.\nPatients will receive 4 cycles of 1 week treatment unless there is unacceptable toxicity or withdrawal of consent.\nF8IL10 will be administered intravenously. MTX can be administered orally, subcutaneously or intramuscularly. Folic acid will be administered orally.\nStudy design :\nCoohort 1 to 6 --> 10-15 mg MTX (fixed)  + 6/15/30/60/110/160/210 \u03bcg/kg F8IL10 (one dosage for each coohort)\nACR and DAS28 responses and safety evaluation will be recorded after 4 cycles of treatment. Patients willing to continue the treatment will receive additional 4 cycles of treatment at the dose they received during the first 4 cycles.", 
            "intervention_name": "F8IL10 in combination with methotrexate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "F8", 
            "IL10", 
            "Interleukin", 
            "monoclonal", 
            "antibody", 
            "Rheumatoid Arthritis"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Roberto Caporali, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }, 
                    "name": "Policlinico San Matteo Pavia"
                }, 
                "investigator": {
                    "last_name": "Roberto Caporali, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stefano Bombardieri, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy"
                    }, 
                    "name": "University Hospital Pisa"
                }, 
                "investigator": {
                    "last_name": "Stefano Bombardieri, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giandomenico Sebastiani, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera San Camillo Forlanini Roma"
                }, 
                "investigator": {
                    "last_name": "Giandomenico Sebastiani, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mauro Galeazzi, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Universitaria Senese"
                }, 
                "investigator": {
                    "last_name": "Mauro Galeazzi, prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis", 
        "overall_contact": {
            "last_name": "Leonardo Giovannoni, Dr", 
            "phone": "(0039) 0577 588539"
        }, 
        "overall_official": {
            "affiliation": "Azienda Ospedaliera Universitaria Senese", 
            "last_name": "Michele Maio, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: National Institute of Health", 
                "Italy: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Establish the MTD and the RD of F8IL10 when administered in combination with methotrexate", 
                "measure": "Maximum tolerated dose (MTD) and recommended dose (RD)", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Evaluation of the type and the number of adverse events eventually present", 
                "measure": "Safety and tolerability of the combination treatment with F8IL10 and metotrexate", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076659"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile of F8IL10", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Evaluate the possible induction of human anti-fusion protein antibodies (HAFA) formation through standard laboratory analysis.", 
                "measure": "Human anti-fusion protein antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks"
            }, 
            {
                "description": "ACR and DAS28 criteria", 
                "measure": "Antiarthritic activity", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Philogen S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philogen S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}